Citations

Clear

512 citation(s) found for "Turner, ST".

Evaluation of previously embolized intracranial aneurysms: inter-and intra-rater reliability among neurosurgeons and interventional neuroradiologists
Lakomkin, Nikita , Magarik, Jordan A., Stephens, Marcus L., Akinpelu, Babatunde , Spiotta, Alejandro M , Ahmed, Azam , Hirsch, Joshua A , James, Robert F. , Kallmes, David F. , Meyers, Philip M. , Niemann, David , Rasmussen, Peter A. , Turner, Raymond D , Welch, Babu G. , Zuckerman, Scott L. , Vargas, Jan , Arthur, Adam Stephen , Fiorella, David , Hanel, Ricardó A. , Hui, Ferdinand , Mocco, J

Mayo Clinic

Journal of NeuroInterventional Surgery | September 16, 2017 | Volume: 10 | Issue: 5 | Pages: 462-466

10.1136/neurintsurg-2017-013231 | PMID 28918386 Get It

Background The angiographic evaluation of previously coiled aneurysms can be difficult yet remains critical for determining re-treatment. Objective The main objective of this study was to determine the inter-rater reliability for both the Raymond Scale and per cent embolization among a group of neurointerventionalists evaluating previously embolized aneurysms. Methods A panel of 15 neurointerventionalists examined 92 distinct cases of immediate post-coil embolization and 1 year post-embolization angiographs. Each case was presented four times throughout the study, along with alterations in demographics in order to evaluate intra-rater reliability. All respondents were asked to provide the per cent embolization (0–100%) and Raymond Scale grade (1-3) for each aneurysm. Inter-rater reliability was evaluated by computing weighted kappa values (for the Raymond Scale) and intraclass correlation coefficients (ICC) for per cent embolization. Results 10 neurosurgeons and 5 interventional neuroradiologists evaluated 368 simulated cases. The agreement among all readers employing the Raymond Scale was fair (κ=0.35) while concordance in per cent embolization was good (ICC=0.64). Clinicians with fewer than 10 years of experience demonstrated a significantly greater level of agreement than the group with greater than 10 years (κ=0.39 and ICC=0.70 vs κ=0.28 and ICC=0.58). When the same aneurysm was presented multiple times, clinicians demonstrated excellent consistency when assessing per cent embolization (ICC=0.82), but moderate agreement when employing the Raymond classification (κ=0.58). Conclusions Identifying the per cent embolization in previously coiled aneurysms resulted in good inter- and intra-rater agreement, regardless of years of experience. The strong agreement among providers employing per cent embolization may make it a valuable tool for embolization assessment in this patient population.
Gene Variant of the Bradykinin B2 Receptor Influences Pulmonary Arterial Pressures in Heart Failure Patients
Olson, Thomas P. , Bailey, Kent R. , Wood, Christina M., Johnson, Bruce D. , Frantz, Robert P. , Turner, Stephen T.

Mayo Clinic

Clinical medicine. Circulatory, respiratory and pulmonary medicine | September 13, 2017 | Volume: 3 | Issue: No issue available | Pages: CCRPM.S2147

10.4137/ccrpm.s2147 Get It

Background Pulmonary arterial pressure (PAP) varies considerably in heart failure (HF) despite similar degrees of left ventricular (LV) dysfunction. Bradykinin alters vascular tone and common variations in the kinin B2 receptor (BDKRB2) gene exists. We hypothesized that genetic variation in this receptor would influence PAP in HF. Methods 131 HF patients (>1yr history systolic HF), without COPD, not currently smoking, BMI < 40, without atrial fibrillation completed the study which included a blood draw for genotyping and neurohormones (ACE, A-II, Bradykinin, ANP, BNP, and catecholamines), an echocardiogram for cardiac function and systolic PAP (PAPsys). Results Mean LVEF was 29% ∓ 12%, NYHA class 2 ∓ 1, age 56 ∓ 12 yr, BMI 28 ∓ 5 kg/m 2 . Forty-six patients (35%) were homozygous for the +9 allele, 58 (44%) were heterozygous (+9/-9) and 27 (21%) were homozygous for the -9 allele of the BDKRB2. PAPsys averaged 42 ∓ 13, 38 ∓ 12, and 35 ∓ 11 mmHg for +9/+9, +9/-9 and -9/-9, respectively (p = 0.03). There was a trend towards gene effect for plasma ACE with the highest values in +9/+9 and lowest in -9/-9 patients (9.5 ∓ 10.7, 7.1 ∓ 8.7, and 5.4 ∓ 6.4 U/L, respectively, p = 0.06). There were no differences in plasma bradykinin or A-II, LVEF, or NYHA across genotypes. Conclusion These data suggest the +9/+9 polymorphism of the BDKRB2 receptor influences pulmonary vascular tone in stable HF.
Relationships of Clinical and Computed Tomography-Imaged Adiposity with Cognition in Middle-Aged and Older African Americans
Parker, Kirby G., Lirette, Seth T. , Deardorff, David S, Bielak, Lawrence F. , Peyser, Patricia A. , Carr, J. Jeffrey , Terry, James G. , Fornage, Myriam , Benjamin, Emelia J. , Griswold, Michael , Windham, B. Gwen , Turner, Stephen T. , Benjamin, Emelia J , Mosley, Thomas H. , Terry, James G , Lirette, Seth

Mayo Clinic

The Journals of Gerontology: Series A | August 31, 2017 | Volume: 73 | Issue: 4 | Pages: 492-498

10.1093/gerona/glx163 | PMID 28958070 Get It

Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5
Nguyen, Tien, Barry, Mary , Turner, Mallory, Crosby, Catherine, Trujillo, Miguel, Morris, John, Barry, Michael, Barry, Michael A. , Turner, Mallory A., Crosby, Catherine M. , Trujillo, Miguel A., Barry, Michael A

Mayo Clinic

Biomedicines | August 10, 2017 | Volume: 5 | Issue: 3 | Pages: 46

10.3390/biomedicines5030046 | PMID 28796161 Get It

Oncolytic viruses would ideally be of use for systemic therapy to treat disseminated cancer. To do this safely, this may require multiple layers of cancer specificity. The pharmacology and specificity of oncolytic adenoviruses can be modified by (1) physical retargeting, (2) physical detargeting, (3) chemical shielding, or (4) by modifying the ability of viral early gene products to selectively activate in cancer versus normal cells. We explored the utility of these approaches with oncolytic adenovirus serotype 5 (Ad5) in immunocompetent Syrian hamsters bearing subcutaneous HaK tumors. After a single intravenous injection to reach the distant tumors, the physically hepatocyte-detargeted virus Ad5-hexon-BAP was more effective than conditionally replicating Ad5-dl1101/07 with mutations in its E1A protein. When these control or Ad5 treated animals were treated a second time by intratumoral injection, prior exposure to Ad5 did not affect tumor growth, suggesting that anti-Ad immunity neither prevented treatment nor amplified anti-tumor immune responses. Ad5-dl1101/07 was next chemically shielded with polyethylene glycol (PEG). While 5 kDa of PEG blunted pro-inflammatory IL-6 production induced by Ad5-dl1101/07, this shielding reduced Ad oncolytic activity.
Skeletal and Uterotrophic Effects of Endoxifen in Female Rats
Gingery, Anne , Subramaniam, Malayannan , Turner, Russell T. , Pitel, Kevin S., McGovern, Renee M., Marler, Ronald J., Hawse, John R. , Reid, Joel M. , Ingle, James N. , Iwaniec, Urszula T. , Goetz, Matthew P. , Gingery, Anne

Mayo Clinic

Endocrinology | August 3, 2017 | Volume: 158 | Issue: 10 | Pages: 3354-3368

10.1210/en.2016-1871 | PMID 28977607 Get It

Correction: The complex genetics of gait speed: genome-wide meta-analysis approach
Ben-Avraham, Dan, Karasik, David , Verghese, Joe , Lunetta, Kathryn L. , Eicher, John D., Vered, Rotem, Deelen, Joris , Arnold, Alice M. , Buchman, Aron S. , Faul, Jessica D. , Nethander, Maria , Fornage, Myriam , Adams, Hieab H.H. , Matteini, Amy M., Callisaya, Michele L. , Smith, Albert V. , Yu, Lei, Jager, Philip L. De , Evans, Denis A., Guðnason, Vilmundur , Hofman, Albert , Pattie, Alison, Knopman, Davis S., Parimi, Neeta, Bandinelli, Stefania , Beekman, Marian , Gutman, Danielle , Sharvit, Lital , Mooijaart, Simon P. , Liewald, David C. , Houwing‐Duistermaat, Jeanine J. , Ohlsson, Claes , Moed, Matthijs, Hernandez, Dena, Thomson, Russell , Tranah, Gregory J. , Weir, David R. , Zhao, Wei , Starr, John M. , Johnson, Andrew D. , Bennett, David A. , Cummings, Steven R. , Deary, Ian J. , Harris, Tamara B., Kardia, Sharon L. R., Mosley, Thomas H. , Srikanth, Velandai , Windham, B. Gwen , Davies, Gail , Evans, Daniel S. , Ferrucci, Luigi , Atzmon, Gil , Bennett, David A. , Turner, Stephen T. , Smith, Jennifer A. , Tanaka, Toshiko , Corley, Janie , Launer, Lenore J. , Verlinden, Vincentius J.A. , Mellström, Dan , Geest, Jos N. van der , Karlsson, Magnus K , McWhirter, Rebekah , Liu, Ching‐Ti , Uitterlinden, André G. , Ikram, M. Arfan , Newman, Anne B. , Walston, Jeremy D , Slagboom, P. Eline , Kiel, Douglas P. , Murabito, Joanne M. , Adams, Hieab H H , Smith, Albert V , Ferrucci, Luigi , Ohlsson, Claes , Srikanth, Velandai K

Mayo Clinic

Aging | July 7, 2017 | Volume: 9 | Issue: 7 | Pages: 1844-1846

10.18632/aging.101260 | PMID 28696945 Get It

RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis
Lee, Bomi , Turner, Russell T. , Lin, Yi-Wei, Gingery, Anne , Wei, Li‐Na , Clarke, Bart L, Iwaniec, Urszula T. , Clarke, B.L. , Gingery, Anne

Mayo Clinic

JCI Insight | April 6, 2017 | Volume: 2 | Issue: 7 | Pages: No page available

10.1172/jci.insight.90517 | PMID 28405613 Get It

Osteolytic bone diseases, such as osteoporosis, are characterized by diminished bone quality and increased fracture risk. The therapeutic challenge remains to maintain bone homeostasis with a balance between osteoclast-mediated resorption and osteoblast-mediated formation. Osteoclasts are formed by the fusion of monocyte/macrophage-derived precursors. Here we report, to our knowledge for the first time, that receptor-interacting protein 140 (RIP140) expression in osteoclast precursors and its protein regulation are crucial for osteoclast differentiation, activity, and coupled bone formation. In mice, monocyte/macrophage–specific knockdown of RIP140 (mϕRIP140KD) resulted in a cancellous osteopenic phenotype with significantly increased bone resorption and reduced bone formation. Osteoclast precursors isolated from mϕRIP140KD mice had significantly increased differentiation potential. Furthermore, conditioned media from mϕRIP140KD primary osteoclast cultures significantly suppressed osteoblast differentiation. This suppressive activity was effectively and rapidly terminated by specific Syk-stimulated RIP140 protein degradation. Mechanistic analysis revealed that RIP140 functions primarily by inhibiting osteoclast differentiation through forming a transcription-suppressor complex with testicular receptor 4 (TR4) to repress osteoclastogenic genes. These data reveal that monocyte/macrophage RIP140/TR4 complexes may serve as a critical transcription regulatory complex maintaining homeostasis of osteoclast differentiation, activity, and coupling with osteoblast formation. Accordingly, we propose a potentially novel therapeutic strategy, specifically targeting osteoclast precursor RIP140 protein in osteolytic bone diseases.
A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Jack, Clifford R., Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Sadowski, Martin, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Hsiung, Robin, Schultz, Susan, Burns, Jeffrey, Jicha, Gregory, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R. , Hsiung, Ging‐Yuek Robin , Jicha, Gregory A. , Sadowski, Martin , van Dyck, Christopher H, Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Schultz, Susan, Burns, Jeffrey, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1768-1775

10.1212/wnl.0000000000003904 | PMID 28381506 Get It

Defining leadership competencies for pediatric critical care fellows: Results of a national needs assessment
Green, Michael L. , Winkler, Margaret K., Brannen, Melissa L., Bone, Meredith, Maa, Tensing , Arteaga, Grace M. , McCabe, Megan , Marcdante, Karen , Mink, Richard B. , Schneider, James W. , Turner, David A.

Mayo Clinic

Medical Teacher | March 10, 2017 | Volume: 39 | Issue: 5 | Pages: 486-493

10.1080/0142159x.2017.1297527 | PMID 28281362 Get It

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, Gerard , Frye, Mark A. , McDonald, William M. , Turner, Mason S., Schatzberg, Alan F. , Summergrad, Paul , Nemeroff, Charles B. , Mathew, Sanjay J.

Mayo Clinic

JAMA Psychiatry | March 1, 2017 | Volume: 74 | Issue: 4 | Pages: 399

10.1001/jamapsychiatry.2017.0080 | PMID 28249076 Get It